Literature DB >> 24824564

Cancer cell-selective promoter recognition accompanies antitumor effect by glucocorticoid receptor-targeted gold nanoparticle.

Samaresh Sau1, Pritha Agarwalla, Sudip Mukherjee, Indira Bag, Bojja Sreedhar, Manika Pal-Bhadra, Chitta Ranjan Patra, Rajkumar Banerjee.   

Abstract

Nanoparticles, such as gold nanoparticles (GNP), upon convenient modifications perform multi tasks catering to many biomedical applications. However, GNP or any other type of nanoparticles is yet to achieve the feat of intracellular regulation of endogenous genes of choice such as through manipulation of a gene-promoter in a chromosome. As for gene modulation and delivery, GNP (or other nanoparticles) showed only limited gene therapy potential, which relied on the delivery of 'exogenous' genes invoking gene knockdown or replacement. Practically, there are no instances for the nanoparticle-mediated promoter regulation of 'endogenous' genes, more so, as a cancer selective phenomenon. In this regard, we report the development of a simple, easily modifiable GNP-formulation, which promoted/up-regulated the expression of a specific category of 'endogenous' genes, the glucocorticoid responsive genes. This genetic up-regulation was induced in only cancer cells by modified GNP-mediated transcriptional activation of its cytoplasmic receptor, glucocorticoid receptor (GR). Normal cells and their GR remained primarily unperturbed by this GNP-formulation. The most potent gene up-regulating GNP-formulation down-regulated a cancer-specific proliferative signal, phospho-Akt in cancer cells, which accompanied retardation of tumor growth in the murine melanoma model. We show that GR-targeted GNPs may find potential use in the targeting and modulation of genetic information in cancer towards developing novel anticancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24824564     DOI: 10.1039/c4nr00974f

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  16 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Immunotherapy and molecular role of T-cell in PD-1 antibody treated resectable lung cancer patients.

Authors:  Samaresh Sau; Arun K Iyer
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Nano-engineered delivery systems for cancer imaging and therapy: Recent advances, future direction and patent evaluation.

Authors:  Ghazal Nabil; Ketki Bhise; Samaresh Sau; Mohamed Atef; Hossny A El-Banna; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-08-16       Impact factor: 7.851

4.  CD44 directed nanomicellar payload delivery platform for selective anticancer effect and tumor specific imaging of triple negative breast cancer.

Authors:  Zhaoxian Wang; Samaresh Sau; Hashem O Alsaab; Arun K Iyer
Journal:  Nanomedicine       Date:  2018-04-17       Impact factor: 5.307

5.  Nanomechanical Insight of Pancreatic Cancer Cell Membrane during Receptor Mediated Endocytosis of Targeted Gold Nanoparticles.

Authors:  Tanmay Kulkarni; Debabrata Mukhopadhyay; Santanu Bhattacharya
Journal:  ACS Appl Bio Mater       Date:  2020-12-30

Review 6.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

Review 7.  A tumor multicomponent targeting chemoimmune drug delivery system for reprograming the tumor microenvironment and personalized cancer therapy.

Authors:  Samaresh Sau; Katyayani Tatiparti; Hashem O Alsaab; Sushil K Kashaw; Arun K Iyer
Journal:  Drug Discov Today       Date:  2018-03-15       Impact factor: 7.851

8.  Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.

Authors:  Sujan Kumar Mondal; Sudhakar Jinka; Krishnendu Pal; Swetha Nelli; Shamit Kumar Dutta; Enfeng Wang; Ajaz Ahmad; Khalid M AlKharfy; Debabrata Mukhopadhyay; Rajkumar Banerjee
Journal:  Mol Pharm       Date:  2016-06-01       Impact factor: 4.939

9.  The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis.

Authors:  Katharina Birkner; Beatrice Wasser; Julia Loos; Alexander Plotnikov; Rony Seger; Frauke Zipp; Esther Witsch; Stefan Bittner
Journal:  Int J Mol Sci       Date:  2017-09-15       Impact factor: 5.923

Review 10.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.

Authors:  Hashem O Alsaab; Samaresh Sau; Rami Alzhrani; Katyayani Tatiparti; Ketki Bhise; Sushil K Kashaw; Arun K Iyer
Journal:  Front Pharmacol       Date:  2017-08-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.